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Abstract
Little information is available about survival of high-risk pediatric neuroblastoma patients in 
developing countries. We aimed to assess survival among high-risk pediatric neuroblastoma 
patients in La Plata, Argentina. Individuals eligible for our cohort were aged <20 years when 
diagnosed with high-risk neuroblastoma and received cancer-directed therapy including stem cell 
transplantation at Hospital de Niños Sor Maria Ludovica between February 1999 and February 
2015. We estimated overall survival probabilities using an extended Kaplan-Meier approach. Our 
study population comprised 39 high-risk neuroblastoma patients, of whom 39% were aged >4 
years at diagnosis, 54% were male, and 62% had adrenal neuroblastoma. We observed 18 deaths, 
and the median survival time of our study population was 1.7 years. The 5-year overall survival 
probability was 24% (95% confidence limits [CL]: 10%, 41%). In contrast, 5-year survival of 
high-risk neuroblastoma patients ranges between 23% and 76% in developed countries. Survival 
among high-risk neuroblastoma patients is generally poor regardless of geographic location, but 
our results illustrate dramatically worse survival for patients in a developing country. We speculate 
that the observed survival differences could be attenuated or eliminated with improvements in 
treatment and supportive care, but addressing these issues will require creative solutions because 
of resource limitations.
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INTRODUCTION
Low- and intermediate-risk neuroblastoma, characterized by favorable stages and age <1 
year at time of diagnosis, have 5-year overall survival >90% following chemotherapy and 
surgical resection. In contrast, 5-year overall survival for high-risk neuroblastoma, 
characterized by features such as metastasis, age >1 year, and amplified MYCN oncogene, is 
only 40 – 50% despite intensive treatment protocols that include chemotherapy, surgery, 
radiation, and stem cell transplantation.(1, 2) The current evidence about survival among 
high-risk neuroblastoma patients is almost exclusively derived from cohorts in developed 
countries. Nevertheless, the burden of pediatric neuroblastoma is nearly as high in 
developing countries such as Argentina as in developed countries such as the United States 
(age-standardized incidence=7.9(3) and 10 per million children,(4) respectively). Evidence 
from developing countries may help identify survival disparities among high-risk pediatric 
neuroblastoma patients compared with developed countries. Therefore, we aimed to describe 
survival among high-risk pediatric neuroblastoma patients in Argentina and compare 
survival between our setting and other settings.
METHODS
Study population
Hospital de Niños Sor Maria Ludovica in La Plata, Argentina is a public institution that 
serves patients regardless of insurance status. The pediatric oncology unit of the hospital 
includes 17 beds for inpatient care of children with hematologic malignancies and solid 
tumors. In addition to serving the local catchment area, Hospital de Niños Sor Maria 
Ludovica is a referral center for high-risk pediatric neuroblastoma patients from hospitals in 
Argentina and neighboring countries.
Individuals eligible for our cohort were aged <20 years when diagnosed with high-risk 
neuroblastoma and received cancer-directed therapy including stem cell transplantation at 
Hospital de Niños Sor Maria Ludovica in La Plata, Argentina between February 1999 and 
February 2015. Consistent with national guidelines in Argentina, high-risk neuroblastoma 
was defined as meeting one of the following criteria: 1) age ≥1 year and disseminated 
disease (stage 4 of International Neuroblastoma Staging System [INSS] or stage M of 
International Neuroblastoma Risk Group Staging System [INRGSS]); 2) stages 2 or 3 
(INSS) or L1, L2, or MS (INRGSS) with MYCN amplification, or 3) age <1 year with 
MYCN amplification. High-risk neuroblastoma patients were treated according to modified 
N7(5) or European SIOP Neuroblastoma (SIOPEN HR-NBL1(6)) protocols. The induction 
therapy backbone included cyclophosphamide, doxorubicin, and vincristine (courses 1,2, 
and 4), and cisplatin and etoposide (courses 3 and 5). Consolidation therapy involved 
administration of busulfan (p.o. 4 times per day) and melphalan, with 13-cis retinoic acid 
administered following autologous stem cell transplantation. Supportive care included 
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prophylaxis with acyclovir and trimethoprim-sulfamethoxazole. The treatment approach 
remained largely unchanged throughout the study period. This study was considered exempt 
from institutional review board oversight.
Variables
Medical records containing prospectively documented patient information from time of 
neuroblastoma diagnosis were abstracted using a standardized data collection form. Baseline 
information included demographic and clinical characteristics such as neuroblastoma 
diagnosis and location of primary tumor. We defined malnourishment as a weight for age z-
score <−2 using the World Health Organization reference population.(7) Resource 
limitations in this setting precluded systematic assessments of prognostic factors such as 
DNA ploidy, MYCN gene amplifications, 1p36 deletions, and serum biomarkers. Follow-up 
information included basic data about the stem cell transplantation procedure and mortality.
Data analysis
Prior studies of survival among high-risk pediatric neuroblastoma patients used inconsistent 
measures of survival duration. Some studies measured survival since the time of 
neuroblastoma diagnosis and others measured survival since the time of stem cell 
transplantation. Unfortunately, neither of these approaches properly accounted for the time 
between diagnosis and transplantation, which can result in biased survival probabilities (8) if 
the goal is to estimate survival after transplantation. Consequently, we used an extended 
Kaplan-Meier approach for estimating survival probabilities.(8) We used age as the time-
scale,(9) where person-time was observed from the age of neuroblastoma diagnosis, but 
entry into the cohort did not occur until the age at transplantation (i.e. delayed entry). For 
comparative purposes, we also estimated overall survival probabilities using the age of 
neuroblastoma diagnosis and the age of transplantation, respectively. Patients contributed 
follow-up time until death, loss to follow-up, or end of the study period (May 1, 2015).
Comparison of survival with other populations
We systematically searched PubMed/Medline for published reports regarding overall 
survival among high-risk pediatric neuroblastoma patients who underwent autologous stem 
cell transplantation. We used combinations of the search terms: pediatric OR paediatric OR 
child; neuroblastoma; high-risk OR advanced; and overall survival. Eligible reports were 
published between 2000 and 2016, and reported 5-year overall survival probabilities. 
Reviews, editorials, commentaries, and phase 1 or phase 2 randomized controlled trials 
(because of limited follow-up in such studies) were excluded. We abstracted information 
pertaining to each study, including publication year, study period, region, sample size, 
consolidation therapy, the measure of survival duration (time since diagnosis or 
transplantation), and 5-year overall survival probabilities specific to high-risk pediatric 
neuroblastoma patients who underwent autologous stem cell transplantation.
We estimated 5-year survival differences, which individually compared the 5-year overall 
survival probabilities reported in eligible studies with the 5-year overall survival probability 
observed in our study. To estimate 95% confidence limits (CL) for the survival difference, 
we first estimated the standard errors (SE) for 5-year overall survival probabilities based on 
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the reported 95% CL from eligible studies, where SE = (upper limit of CL – lower limit of 
CL)/3.92.
These standard errors were then used to compute standard errors for the survival difference 
(SESD) as follows(10):
where SEA was the standard error of the reported 5-year survival probability and SEB was 
the standard error of 5-year survival probability observed in our study. The corresponding 
95% CL were then computed as: point estimate for survival difference ± 1.96*SESD.
RESULTS
The eligible population comprised 40 high-risk pediatric neuroblastoma patients, but 
incomplete information for one patient resulted in a study population of 39 patients. Table 1 
summarizes the characteristics of our study population. Briefly, the majority of patients 
(56%) were transplanted between 2000 and 2007. Patients were primarily aged ≤4 years 
(61%) at diagnosis and the majority were males (54%). The most common site of 
neuroblastoma was the adrenal gland (62%). The prevalence of malnourishment was low 
(2.6%) for patients with available evaluable data (average prevalence for hospitalized 
patients in Argentina is 12% (11)). The median follow-up for surviving patients was 1.7 
years (interquartile range = 1.2 – 7.9).
Figure 1 illustrates the survival curves for our study population based on approaches used in 
prior studies and the approach that accounts for time to transplantation. We observed 18 
observed deaths, of which 15 were attributable to disease progression, 1 was attributable to 
pulmonary aspergillosis, 1 was attributable to engraftment failure, and 1 was attributable to 
sepsis. The median survival for this cohort was 1.7 years and the 5-year overall survival 
probability was 24% (95% CL: 10%, 41%) when accounting for time to transplant. The 
median survival was 2.4 years and 0.74 years if age at neuroblastoma diagnosis and age at 
transplant, respectively, were designated as the start of observation.
Table 2 describes 13 published reports,(12–24) and the current study, of 5-year overall 
survival among high-risk pediatric neuroblastoma and summarizes survival differences 
compared with our population. Half of the reports pertained to high-risk pediatric 
neuroblastoma cohorts in North America. The median sample size was 43 (interquartile 
range=26 – 89). Consolidation regimens were heterogeneous across studies, but 57% 
included either total body or localized radiation. Survival duration was measured as time 
since transplantation in 46% of studies. Except for one study,(24) the 5-year overall survival 
estimate in our population was lower than other populations, with the largest 5-year absolute 
survival difference being 52% (95% CL: 33%, 71%).
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DISCUSSION
We analyzed data from 39 patients observed over 16 years in La Plata, Argentina to address 
a gap in the literature about survival of high-risk pediatric neuroblastoma patients treated 
with stem cell transplantation in developing countries. Our results suggest markedly worse 
survival in this setting compared with high-risk pediatric neuroblastoma patients in North 
America, Europe, and Asia. Specifically, 5-year overall survival in our setting was 24% 
(95% CL: 10%, 41), whereas the highest reported 5-year overall survival in North America 
was 76% (95% CL: 66%, 88%) in a highly select group of high-risk pediatric neuroblastoma 
patients.(12) In addition, our review of prior studies suggests considerable variation in 
survival even between developed countries. Nevertheless, several issues warrant 
consideration when interpreting the survival estimate for our population and the survival 
differences that compare our estimates with published estimates.
Our overall survival estimate may be sensitive to bias from diverse mechanisms. For 
example, neuroblastoma may be underdiagnosed in developing countries.(25) If children 
with high-risk pediatric neuroblastoma, who would have been eligible for inclusion in our 
study, died before being diagnosed and these children had a rapid course of disease, then the 
survival probabilities in our study may be overestimated. Even if neuroblastoma were 
diagnosed, the standard criteria for high-risk neuroblastoma evolved over the course of our 
study period. Although all patients in our study population met current criteria, certain 
neuroblastoma patients might have been high-risk but unidentified, particularly considering 
the lack of systematic cytogenetic assessment in our setting. We speculate that if any high-
risk neuroblastoma patients were excluded from our study population, our survival 
probabilities are overestimated because survival of unidentified but eligible high-risk 
patients would have been poor without appropriate therapy. Lastly, similar to other studies of 
pediatric cancer populations in developing countries,(26) loss to follow-up was common in 
our study. Loss to follow-up was censored in our analysis, but the evidence does not suggest 
that patients would have survived without completing therapy. Consequently, this 
mechanism of bias would also result in overestimated survival probabilities in our study.
The estimated 5-year survival differences between our setting and other settings may be 
largely attributable to differences in treatment protocols and supportive care.(26, 27) The 5-
year survival difference was greatly attenuated (4.2%, 95% CL: −25%, 33%; 11%, 95% CL: 
−8.1%, 30%) when our setting was compared with settings that used a similar consolidation 
regimen.(15, 17) In addition, treatment delays, host prognostic factors, and environmental 
factors may contribute to variation in survival between settings.(26, 28)
In summary, survival among high-risk neuroblastoma patients is generally poor regardless of 
geographic location, but our results illustrate dramatically worse survival for high-risk 
neuroblastoma patients in a developing country. We speculate that the observed survival 
differences could be attenuated or eliminated with improvements in treatment and supportive 
care, but addressing these issues will require creative solutions because of resource 
limitations. These resource limitations may be addressed with a focus on capacity building 
through collaborative efforts.(28) For example, twinning programs, which are based on 
partnering and interaction between hospitals in developing countries and cancer centers in 
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developed countries, have improved survival and outcomes for pediatric cancer patients in 
developing countries.(29, 30) Despite the success of twinning programs, this approach has 
not been specifically applied in the context of high-risk neuroblastoma. Future studies are 
needed to assess the effectiveness of twinning programs and other approaches for improving 
survival among high-risk neuroblastoma patients in developing countries.
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Figure 1. 
Survival curves for high-risk pediatric neuroblastoma patients in La Plata, Argentina based 
on the measure of survival duration.
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Table 1
Characteristics of high-risk pediatric neuroblastoma patients treated in La Plata, Argentina between February 
1999 and February 2015.
Characteristic n (%)
Transplant period
 2000 – 2007 22 (56)
 2008 – 2015 17 (44)
Age at diagnosis
 >4 years 15 (39)
 ≤4 years 24(61)
Age at transplantation
 >4 years 23 (59)
 ≤4 years 16 (41)
Sex
 Male 21 (54)
 Female 18 (46)
Site of primary tumor
 Adrenal 24 (62)
 Retroperitoneal 7 (18)
 Mediastinal 3 (7.7)
 Other 5 (13)
Malnourisheda
 Yes 1 (2.6)
 No 29 (97)
Vital status at end of study
 Alive 21 (46)
 Deceased 18 (54)
a
Malnourished status based on weight-for-age z-score at the time of transplantation and the World Health Organization reference standard. 
Unreliable or missing data precluded z-score estimation for 9 patients.
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